Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer

NCT00123877 is registered in ClinicalTrials.gov with Gem Pharmaceuticals as lead sponsor.

NCT NCT00123877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00123877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer
Lead sponsor
Gem Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2005
Completion date
November 30, 2005
Enrollment
40
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastasis